Persistence of Immune Response After Vaccination With Influenza Vaccine

Status Completed

Clinical Trial Summary

This clinical study will be performed in subjects aged 12-60 years old enrolled in NCT01310374 who received 2010 seasonal influenza vaccine to evaluate the persistence of the immune response of influenza vaccine up to 24 months after vaccination.

Clinical Trial Description

Subjects were previously vaccinated at 12 to 60 years of age with 2010 seasonal influenza vaccine.The persistence phase starts 24 months after the primary vaccination and blood samples will be taken at 6, 12, 18 and 24 months after primary vaccination. Subjects whose antibody titer less than 1:40 at 6 months after primary vaccination will receive a booster dose of influenza vaccine. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01906190
Study type	Interventional
Source	Centers for Disease Control and Prevention, China
Contact
Status	Completed
Phase	N/A
Start date	August 2011
Completion date	July 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03442582` - Afluria Pregnancy Registry
Completed	`NCT03275389` - A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years	Phase 1
Completed	`NCT05981846` - A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19	Phase 2
Completed	`NCT05044195` - A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age	Phase 3
Completed	`NCT02914275` - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.	Phase 3
Completed	`NCT04590066` - Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy	N/A
Recruiting	`NCT03778203` - Development of Childhood Anti-influenza Immunity	Phase 4
Completed	`NCT04527614` - Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection	N/A
Terminated	`NCT03658629` - Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults	Phase 2
Completed	`NCT05269290` - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections	Phase 3
Completed	`NCT06385821` - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus	Phase 3
Completed	`NCT02867358` - A Clinical Trial of KT07 Capsule in the U.S.A	Phase 2
Withdrawn	`NCT02883972` - Childhood Influenza Immunisation Invitation Trial in Schools	N/A
Completed	`NCT02998996` - Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU	Phase 1/Phase 2
Completed	`NCT02984280` - Specific Respiratory Infections as Triggers of Acute Medical Events	N/A
Completed	`NCT02545543` - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age	Phase 3
Completed	`NCT02243774` - Mail Outreach To Increase Vaccination Acceptance Through Engagement	N/A
Completed	`NCT02621164` - Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents	Phase 3
Completed	`NCT02212106` - A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years	Phase 4
Completed	`NCT02344134` - Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects	Phase 3